Related Experiment Videos
The role of clinical nonfatal end points in cardiovascular phase II/III clinical trials
C M O'Connor1, W A Gattis, T J Ryan
1Duke University Medical Center, Durham, NC 27710, USA.
American Heart Journal
|March 31, 2000
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Risk factors for acute toxoplasmosis in England and Wales.
Epidemiology and infection·2016
The influence of status and the social environment on energy stores in a social fish.
Journal of fish biology·2016
Therapeutic implications of biomarkers in chronic heart failure.
Clinical pharmacology and therapeutics·2013
Disability in atypical parkinsonian syndromes is more dependent on memory dysfunction than motor symptoms.
Parkinsonism & related disorders·2013
Design and Rationale of the CLASP II TR Randomized Trial for Severe Tricuspid Regurgitation.
American heart journal·2026
Design and baseline characteristics of the CagriSema cardiovascular outcomes trial (REDEFINE 3).
American heart journal·2026
Echocardiography-based multimodal models for thromboembolic risk prediction in atrial fibrillation: a narrative review.
Journal of thoracic disease·2026
Coexistence of Ebstein Anomaly and Cerebral Cavernous Malformation: A Case Report.
Clinical case reports·2026
Achieved systolic blood pressure and cardiovascular outcomes in advanced chronic kidney disease.
Clinical kidney journal·2026
Multimodal MRI to elucidate cross-organ coupling mechanisms of the heart-brain axis.
Frontiers in cardiovascular medicine·2026